|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Supplementary Table 7.** Comparisons of performance among the developed models predicting 18-month progression-free survival | | | | |
| Model | Regression-based | | | Score-based | |
| Training AUC | Test AUC | AUC | | |
| CA-125, residual tumor 1 | 0.640 | 0.437 | 0.647 | | |
| CA-125, residual tumor 1, germline *BRCA* status | 0.709 | 0.544 | 0.711 | | |
| CA-125, 6 protein biomarkers 2 | 0.863 | 0.772 | 0.829 | | |
| CA-125, residual tumor 1, germline *BRCA* status, FIGO stage, 6 protein biomarkers 2 | 0.898 | 0.776 | 0.855 | | |
| 1 Residual tumor after debulking surgery.  2 Expression levels of AAT, NFKB, PMVK, VAP1, FABP4, and PF4 on immunohistochemical staining of ovarian cancer tissue.  All variables were binarized as follows: CA-125 (≥700 vs. <700 IU/ml); residual tumor (gross vs. no gross); germline *BRCA* mutation (mutation vs. wild-type); FIGO stage (III-IV vs. I-II); 6 protein biomarkers (high expression vs. low expression).  Abbreviations: AUC, area under the receiver operating characteristic curve; CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics. | | | | |